Hematology & Medical Oncology
Dr. Khuri's clinical interests include thoracic and head and neck oncology. His research interests include the development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco-related cancers. His team is investigating the mechanism of action of signal transduction inhibitors in lung and aerodigestive tract cancers. Dr. Khuri is an accomplished molecular oncologist who has conducted seminal research on oncolytic viral therapy. He has developed molecular-targeted therapeutic approaches for lung and head and neck tumors that combine signal transduction inhibitors with chemotherapy, and he has led major chemoprevention efforts in lung and head and neck cancer.
Dr. Khuri is Editor-in-Chief of Cancer and Chair of the International Advisory Committee for the American University of Beirut Medical School.
Dr. Khuri serves as Principal Investigator of the NCI P01 entitled “Targeting Cell Signaling in Lung Cancer to Enhance Therapeutic Efficacy” (Haian Fu, PhD, co-PI), and as co-Principal Investigator of the Emory Head and Neck Cancer SPORE (Dong M. Shin, MD, PI) and the Emory Chemical Biology Discovery Center (Haian Fu, PhD, PI).
Dr. Khuri’s contributions in cancer research and patient care have been recognized by a number of institutional and national awards, including the prestigious Nagi Sahyoun Award in 2006 by the Middle East Medical Assembly for "his outstanding contributions to clinically relevant scientific research,” election to the American Society of Clinical Investigation in 2007, and the Waun Ki Hong Award from MD Anderson for his "pioneering work on targeting signaling pathways in lung and aerodigestive cancers" in 2010.